Brief: Nabriva Therapeutics Enters Into Exclusive Agreement To Promote And Distribute Sivextro In U.S.
15/07/2020 21:12
July 15 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS ENTERS INTO EXCLUSIVE AGREEMENT TO
PROMOTE
AND DISTRIBUTE SIVEXTRO® (TEDIZOLID PHOSPHATE) IN THE U.S.
* NABRIVA THERAPEUTICS - ACCRETIVE DEAL CREATES SYNERGIES &
SCALE
THAT STRENGTHEN CO'S COMMERCIALIZATION ORGANIZATION TO OPTIMIZE
PRODUCT UPTAKE
* NABRIVA - TO PROCURE SIVEXTRO FROM MERCK & CO. INC.,
KENILWORTH,
N.J., USA, BE RESPONSIBLE FOR DISTRIBUTION OF SIVEXTRO IN U.S.
THROUGH DEC 31, 2023
* NABRIVA THERAPEUTICS - ENGAGED AMPLITY HEALTH TO PROVIDE
COMMUNITY-BASED COMMERCIAL & SALES SERVICES FOR SIVEXTRO &
XENLETA IN U.S.
Source text for Eikon: ID:nGNX5jlwpK
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update